389139-89-3

Usage

Uses

Used in Pharmaceutical Industry:
PTK 0796 is used as an active pharmaceutical ingredient for its potent antimicrobial and antibacterial properties. It demonstrates efficacy against various bacterial strains, such as Bacillus anthracis and Yersinia pestis, making it a valuable asset in the development of new antibiotics to combat drug-resistant infections.
Additionally, PTK 0796 is used as a novel aminomethylcycline antibiotic in clinical development for community-acquired bacterial pneumonia (CABP). Its unique structure and properties contribute to its effectiveness in treating this common respiratory infection.
Used in Drug Delivery Systems:
In the field of drug delivery, PTK 0796 is utilized as a component in the development of innovative drug delivery systems. Its properties allow for the enhancement of drug solubility, stability, and targeted delivery, improving the overall bioavailability and therapeutic outcomes of various medications.
These applications highlight the versatility and potential of PTK 0796 in addressing various challenges in the pharmaceutical and chemical industries, making it a promising compound for further research and development.

Upstream product

• 488818-70-8 (4S,4aS,5aR,12aS)-9-formyl-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide 
• 5813-64-9 2.2-dimethylpropylamine 
• 835877-68-4 C₂₅H₃₃N₅O₇ 
• 630-19-3 pivalaldehyde 
• 13614-98-7 minocycline Hydrochloride 
• 1075240-40-2 C₃₂H₄₂Cl₂N₄O₉ 
• 1075240-41-3 C₃₂H₄₃ClN₄O₉ 
• 2987-16-8 3,3-dimethylbutyrylaldehyde 

Relevant academic research and scientific papers

MINOCYCLINE COMPOUNDS FOR BIODEFENSE

Methods of treating or preventing a bacterial infection in a subject are disclosed herein, wherein the bacterial infection is caused by a bacterium which can be used as a biological weapon. Also disclosed is a pharmaceutical composition comprising the compound of the present invention for treating or preventing a bacterial infection in a subject, wherein the bacterial infection is caused by a bacterium which can be used as a biological weapon.

METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS

Methods for synthesizing a carboxaldehyde substituted tetracycline compound comprising reacting a tetracycline reactive intermediate under appropriate conditions with carbon monoxide, a palladium catalyst, a phosphine ligand, a silane and a base, such that said carboxaldehyde substituted tetracycline compound is synthesized. The palladium catalyst is chosen from PdCl2 (tBu2PhP)2 dichlorobis (di-tert-butylphenylphosphine palladium (II)] or PdCl2 (DPEPhos) [bis (diphenylphosphinophenyl) ether palladium (II) chloride]. The tetracycline reactive intermediate contains moieties selected from halogens and triflates. Methods of synthesizing a substituted tetracycline compound comprising reacting the carboxaldehyde substituted tetracycline compound under palladium catalyzed coupling conditions, hydrogenolysis conditions or reductive amination conditions.

SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND

Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such

METHODS FOR SYNTHESIZING AND PURIFYING AMINOALKYL TETRACYCLINE COMPOUNDS

Methods for the synthesis and purification of 9-amino alkyl tetracycline compounds are described.

Synthesis development of an aminomethylcycline antibiotic via an electronically tuned acyliminium Friedel-Crafts reaction

With the goal of improving the synthetic efficiency, the development of a convergent synthesis of a minocycline derivative PTK0796 via an intermolecular acyliminium Friedel-Crafts reaction (Tscherniac-Einhorn reaction) is described. The entire C9 neopentylaminomethyl side chain was installed in one step using an electronically optimized chloromethylacyliminium precursor in 83% yield. Deprotection and re-equilibration to the C4 α-epimer in the presence of CaCl2 and ethanolamine or NaOH afforded the target aminomethylcycline antibiotic. The corresponding crystalline tosylate salt was found to exhibit improved solid state stability.